ArticleEye (London, England)2026
Bent ab interno needle goniotomy versus gonioscopy-assisted transluminal trabeculotomy in primary open angle glaucoma: a randomised clinical trial, 24-month outcomes.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundTo evaluate and compare 24-month outcomes of Bent Ab interno Needle Goniotomy (BANG) and Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) in pseudophakic primary open angle glaucoma (POAG) patients.
methodsParallel, double-arm, 1:1 ratio, single masked, randomised clinical trial. Pseudophakic POAG eyes with mild to moderate glaucoma and intraocular pressure (IOP) ≥ 18 mmHg under a maximum of 3 antiglaucoma medications were randomised to BANG or GATT. Main outcomes were mean IOP reduction from baseline and surgical success at 24-months. Complete surgical success was defined as IOP ≤ 18 mmHg and 20% IOP reduction from baseline under no medication. Qualified success followed the same parameters, but allowed the use of medication. Additional glaucoma surgery, clinical hypotony or loss of light perception were considered failures.
resultsA total of 45 eyes (22 BANG and 23 GATT) were included. At endpoint, in the BANG and GATT groups, mean IOPs were reduced by 16.0% (p < 0.01) and 22.44% (p < 0.01) (time-group analysis: p = 0.048), whereas medication was reduced by 6.22% (p = 0.89) and 69.78% (p < 0.01) (time-group analysis: p < 0.01), respectively. GATT eyes presented a higher number of medication-free eyes (11 vs. 2, p < 0.01) and IOPs in the low-teens (4 vs. 0, p = 0.02). GATT eyes achieved higher rates of complete (55.0% vs. 4.5%, p < 0.01) and qualified success (64.7% vs. 11.4%, p < 0.01). Additional surgery was needed in 3 (13.63%) BANG eyes and 4 (18.18%) GATT eyes (p = 1.0).
conclusionGATT eyes achieved higher success rates, lower mean IOPs and required less antiglaucoma medication than BANG eyes after 24-months. Both techniques showed a good safety profile and low need for additional surgery.
Identifiers
42806063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.